Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of two traditional Chinese medicinal herbs, *Ligusticum chuanxiong* (Chuanxiong) and Frankincense (Ru Xiang). *Ligusticum chuanxiong* is known for its ability to invigorate blood and move Qi, with active constituents like ligustrazine (tetramethylpyrazine) and ferulic acid that exhibit anti-platelet and vasodilatory properties. Frankincense, a resin from *Boswellia* species, is utilized for its potent anti-inflammatory and analgesic effects, primarily attributed to boswellic acids which inhibit 5-lipoxygenase. This combination is a classic herb pair (Dui Yao) in Traditional Chinese Medicine (TCM) used to treat conditions associated with blood stasis and pain, such as dysmenorrhea, traumatic injuries, and inflammatory joint diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ligusticum chuanxiong + frankincense.